18-FDG PET/CT assessment of basal cell carcinoma with vismodegib

Cancer Medicine

Volumn 1, Issue 2, 2012, Pages 230-236

  Thacker, Curtis A ^a,b   Weiss, Glen J ^c   Tibes, Raoul ^d   Blaydorn, Lisa ^c   Downhour, Molly ^c   White, Erica ^c   Baldwin, Jason ^a   Von Hoff, Daniel D ^c   Korn, Ronald L ^a,c  

^a Scottsdale Medical Imaging   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Basal cell carcinoma; Imaging; PET CT; Vismodegib

Indexed keywords

FLUORODEOXYGLUCOSE F 18; VISMODEGIB;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BONE; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LUNG; LYMPH NODE; MALE; METASTASIS; MUSCLE; OVERALL SURVIVAL; PET SCANNER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN; TISSUE METABOLISM;

EID: 84871497102     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.33     Document Type: Article

References (21)

1. Christenson, L. J., T. A. Borrowman, C. M. Vachon, N. M. Tollefson, C. C. Otley, A. L. Weaver, et al. 2005. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 294:681-690.
2. Diepgen, T. L., and V. Mahler. 2002. The epidemiology of skin cancer. Br. J. Dermatol. 146:1-6.
3. Rubin, A. I., E. H. Chen, and D. Ratner. 2005. Basal-cell carcinoma. N. Engl. J. Med. 353:2262-2269.
4. Wadhera, A., M. Fazio, G. Bricca, and O. Stanton. 2006. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol. Online J. 12:7.
5. Hahn, H., C. Wicking, P. G. Zaphiropoulous, M. R. Gailani, S. Shanley, A. Chidambaram, et al. 1996. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841-851.
6. Xie, J., M. Murone, S. M. Luoh, A. Ryan, Q. Gu, C. Zhang, et al. 1998. Activating smoothened mutations in sporadic basal cell carcinoma. Nature 391:90-92.
7. Weiss, G. J., and D. D. Von Hoff. 2010. Hunting the hedgehog pathway. Clin. Pharmacol. Ther. 87:743-747.
8. Von Hoff, D. D., P. M. LoRusso, C. M. Rudin, J. C. Reddy, R. L. Yauch, R. Tibes, et al. 2009. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361:1164-1172.
9. Hoekstra, C. J., S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, et al. 2005. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J. Clin. Oncol. 23:8362.
10. Schelling, M., N. Avril, J. Nährig, W. Kuhn, W. Römer, D. Sattler, et al. 2000. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 18:1689-1695.
11. Kostakoglu, L., M. Coleman, J. P. Leonard, I. Kuji, H. Zoe, S. J. Goldsmith, et al. 2002. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J. Nucl. Med. 43:1018-1027.
12. Therasse, P., S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92:205-216.
13. Wahl, R. L., H. Jacene, Y. Kasamon, and M. A. Lodge. 2009. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50:122S-150S.
14. Weber, W. A., K. Ott, K. Becker, H. J. Dittler, H. Helmberger, N. E. Avril, et al. 2001. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 19:3058-3065.
15. Fosko, S. W., W. Hu, T. F. Cook, and V. J. Lowe. 2003. Positron emission tomography for basal cell carcinoma of the head and neck. Arch. Dermatol. 139:1141-1146.
16. Barksdale, S. K., N. O'Connor, and R. Barnhill. 1997. Prognostic factors for cutaneous squamous cell and basal cell carcinoma. Determinants of risk of recurrence, metastasis, and development of subsequent skin cancers. Surg. Oncol. Clin. N. Am. 6:625-638.
17. Domarus, H., and P. Stevens. 1984. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in literature. J. Am. Acad. Dermatol. 10:1043-1060.
18. Gallamini, A., M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, et al. 2007. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25:3746-3752.
19. Von Hoff, D. D., R. K. Ramanathan, M. J. Borad, D. A. Laheru, L. S. Smith, T. E. Wood, et al. 2011. Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29:4548-4554.
20. Sekulic, A., M. R. Migden, A. E. Oro, L. Dirix, K. D. Lewis, J. D. Hainsworth, et al. 2012. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366:2171-2179.
21. National Institute of Health. 2012. Bethesda, MD. Available at http://www.clinicaltrials.gov (accessed 18 August 2012).